HN2000000026S1 - industrial model square table - Google Patents

industrial model square table

Info

Publication number
HN2000000026S1
HN2000000026S1 HN2000000026F HN2000000026F HN2000000026S1 HN 2000000026 S1 HN2000000026 S1 HN 2000000026S1 HN 2000000026 F HN2000000026 F HN 2000000026F HN 2000000026 F HN2000000026 F HN 2000000026F HN 2000000026 S1 HN2000000026 S1 HN 2000000026S1
Authority
HN
Honduras
Prior art keywords
square table
industrial model
model square
industrial
table
Prior art date
Application number
HN2000000026F
Other languages
Spanish (es)
Inventor
Carlos Roberts Avalos
Original Assignee
Carlos Roberts Avalos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16821799P priority Critical
Application filed by Carlos Roberts Avalos filed Critical Carlos Roberts Avalos
Publication of HN2000000026S1 publication Critical patent/HN2000000026S1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Abstract

EL PRESENTE DISE�O SE REFIERE A UN MODELO INDUSTRIAL DE MESA CUADRADA DISEO THIS REFERS TO AN INDUSTRIAL MODEL SQUARE TABLE
HN2000000026F 1999-11-30 2000-02-23 industrial model square table HN2000000026S1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16821799P true 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
HN2000000026S1 true HN2000000026S1 (en) 2002-10-01

Family

ID=22610585

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2000000026F HN2000000026S1 (en) 1999-11-30 2000-02-23 industrial model square table

Country Status (47)

Country Link
US (1) US7019147B1 (en)
EP (1) EP1235825B1 (en)
JP (2) JP4522635B2 (en)
CN (2) CN101289442A (en)
AP (1) AP1895A (en)
AR (1) AR026633A1 (en)
AT (1) AT316528T (en)
AU (1) AU782077B2 (en)
BG (1) BG65862B1 (en)
BR (1) BR0015911A (en)
CA (1) CA2392973C (en)
CO (1) CO5251455A1 (en)
CR (1) CR6643A (en)
CU (1) CU23132A3 (en)
CZ (1) CZ300789B6 (en)
DE (1) DE60025747T2 (en)
DK (1) DK1235825T3 (en)
DZ (1) DZ3327A1 (en)
EA (1) EA005407B1 (en)
EE (1) EE05350B1 (en)
EG (1) EG24433A (en)
ES (1) ES2256052T3 (en)
GE (1) GEP20033141B (en)
GT (1) GT200000198A (en)
HN (1) HN2000000026S1 (en)
HR (1) HRP20020475B1 (en)
HU (1) HU230829B1 (en)
IL (2) IL149841D0 (en)
IS (1) IS2209B (en)
MA (1) MA26847A1 (en)
MX (1) MXPA02005343A (en)
MY (1) MY128765A (en)
NO (1) NO324043B1 (en)
NZ (1) NZ518280A (en)
PA (1) PA8507601A1 (en)
PE (1) PE08992001A1 (en)
PL (1) PL201784B1 (en)
RS (1) RS50800B (en)
SI (1) SI1235825T1 (en)
SK (1) SK286773B6 (en)
SV (1) SV2002000232A (en)
TN (1) TNSN00228A1 (en)
TR (1) TR200201430T2 (en)
TW (1) TWI258475B (en)
UA (1) UA75055C2 (en)
WO (1) WO2001040217A1 (en)
ZA (1) ZA200204244B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000026S1 (en) * 1999-11-30 2002-10-01 Carlos Roberts Avalos industrial model square table
IL155447D0 (en) 2000-10-20 2003-11-23 Eisai Co Ltd Nitrogenous aromatic ring compounds
CA2479786C (en) 2002-03-27 2011-11-29 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
WO2003105850A1 (en) * 2002-06-18 2003-12-24 Abbott Laboratories 2-aminoquinolines as melanin concentrating hormone receptor antagonists
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
PA8580301A1 (en) * 2002-08-28 2005-05-24 Pfizer Prod Inc New benzimidazole derivatives useful as antiproliferative agents
PL377713A1 (en) 2002-12-19 2006-02-06 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
NZ571898A (en) * 2003-06-24 2010-01-29 Pfizer Prod Inc Reaction of 2-chloro-8-benzyloxyquinoline with 2-nitrophenylamine in the presence of 1,2-bis(diphenylphosphino)ethane (dppe), palladium catalyst and a base
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CN1852905A (en) * 2003-08-21 2006-10-25 Osi制药公司 N-substituted benzimidazolyl c-kit inhibitors
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2005051304A2 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
EP2530075A3 (en) 2004-06-24 2014-12-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
AT428421T (en) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd A medicinal composition with improved stability and reduced gelling
CA2582479C (en) * 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
UA95775C2 (en) 2005-04-26 2011-09-12 Пфайзер Инк. Antibody that specifically binds to p-cadherin
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
KR101536506B1 (en) 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 Human monoclonal antibodies to activin receptor-like kinase-1
ES2374450T3 (en) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Anti-bangeous response biological markers for kinner inhibitors of the growth factor receiver 1 similar to insulin.
LT1993360T (en) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
WO2008022746A1 (en) 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
CN101511793B (en) 2006-08-28 2011-08-03 卫材R&D管理有限公司 Antitumor agent for undifferentiated gastric cancer
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
KR101445892B1 (en) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition for treatment of undifferentiated-type of gastric cancer
CN101679422A (en) * 2007-03-28 2010-03-24 阵列生物制药公司 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
BRPI0809998A2 (en) * 2007-04-03 2014-10-14 Array Biopharma Inc Imidazo [1,2-a] pyridine compound as tyrosine kinase receptor inhibitors
WO2009036101A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
MX361711B (en) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Star Process for making modulators of cystic fibrosis transmembrane conductance regulator.
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
MX340095B (en) 2009-06-12 2016-06-27 Abivax Compounds useful for treating aids.
CN102140099A (en) * 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 Novel pyridine derivative
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
BR112012023660A2 (en) 2010-03-19 2015-09-15 Boston Biomedical Inc new methods to target cancer stem cells
MX2012012145A (en) * 2010-04-28 2012-11-21 Daiichi Sankyo Co Ltd [5,6] heterocyclic compound.
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
MX339899B (en) * 2011-02-25 2016-06-16 Array Biopharma Inc Triazolopyridine compounds as pim kinase inhibitors.
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
CN103958500B (en) * 2011-10-10 2016-04-27 奥赖恩公司 Protein kinase inhibitors
CA2864484C (en) * 2012-02-17 2019-07-02 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CN109966264A (en) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 Pharmaceutical composition and its application
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR20140040594A (en) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 Method of inhibiting mutant c-kit
CN104755463A (en) 2012-12-21 2015-07-01 卫材R&D管理有限公司 Amorphous form of quinoline derivative, and method for producing same
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanib for treatment of mutated flt3 proliferative disorders
AR094403A1 (en) 2013-01-11 2015-07-29 F Hoffmann-La Roche Ag Combination therapy of anti-HER3
JP2016523893A (en) 2013-07-05 2016-08-12 アビバックス Compounds useful for treating diseases caused by retroviruses
US20150119421A1 (en) * 2013-10-25 2015-04-30 Arog Pharmaceuticals, Llc Method of inhibiting flt3 kinase
CA2957005A1 (en) 2014-08-28 2016-03-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3307260A4 (en) 2015-06-12 2019-02-13 Axovant Sciences GmbH Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
EA201891304A1 (en) 2015-12-03 2019-01-31 Агиос Фармасьютикалс, Инк. MAT2A INHIBITORS FOR THE TREATMENT OF MTAP-null MALIGNANT TUMORS
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
WO2018057808A1 (en) * 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) * 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222637D1 (en) * 1991-05-10 1997-11-13 Rhone Poulenc Rorer Int To mono- and bicyclic aryl and heteroaryl derivatives having an inhibitory effect on the EGF and / or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5523408A (en) * 1994-03-25 1996-06-04 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2191187T3 (en) * 1996-07-13 2003-09-01 Glaxo Group Ltd bicyclic heteroaromatic compounds as inhibitors of protein tyrosine kinase.
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998002434A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
HN2000000026S1 (en) * 1999-11-30 2002-10-01 Carlos Roberts Avalos industrial model square table

Also Published As

Publication number Publication date
MA26847A1 (en) 2004-12-20
EE05350B1 (en) 2010-10-15
IL149841A (en) 2008-07-08
TR200201430T2 (en) 2003-01-21
PL355917A1 (en) 2004-05-31
TNSN00228A1 (en) 2005-11-10
CA2392973A1 (en) 2001-06-07
EA005407B1 (en) 2005-02-24
RS50800B (en) 2010-08-31
CA2392973C (en) 2007-05-15
JP2003515603A (en) 2003-05-07
PE08992001A1 (en) 2001-09-05
IS6341A (en) 2002-04-12
SK286773B6 (en) 2009-05-07
BG106812A (en) 2003-01-31
WO2001040217A1 (en) 2001-06-07
CN101289442A (en) 2008-10-22
AU1048001A (en) 2001-06-12
BR0015911A (en) 2002-08-06
IL149841D0 (en) 2002-11-10
DK1235825T3 (en) 2006-05-15
NO324043B1 (en) 2007-07-30
SI1235825T1 (en) 2006-06-30
EE200200276A (en) 2003-06-16
SV2002000232A (en) 2002-06-07
GT200000198A (en) 2002-05-23
AP200202529A0 (en) 2002-06-30
HRP20020475B1 (en) 2007-06-30
NO20022556L (en) 2002-07-29
CN1402721A (en) 2003-03-12
US7019147B1 (en) 2006-03-28
GEP20033141B (en) 2003-08-11
HRP20020475A2 (en) 2005-10-31
PA8507601A1 (en) 2003-02-14
YU30702A (en) 2005-06-10
HU0203725A2 (en) 2003-02-28
HU230829B1 (en) 2018-08-28
AU782077B2 (en) 2005-06-30
CZ300789B6 (en) 2009-08-12
JP2007126468A (en) 2007-05-24
BG65862B1 (en) 2010-03-31
CR6643A (en) 2003-11-07
CU23132A3 (en) 2006-05-22
HU0203725A3 (en) 2004-05-28
CZ20021759A3 (en) 2003-06-18
MY128765A (en) 2007-02-28
CO5251455A1 (en) 2003-02-28
ZA200204244B (en) 2003-05-28
JP4522635B2 (en) 2010-08-11
PL201784B1 (en) 2009-05-29
AP1895A (en) 2008-10-08
AR026633A1 (en) 2003-02-19
MXPA02005343A (en) 2002-12-11
UA75055C2 (en) 2002-08-15
DE60025747T2 (en) 2006-08-31
EG24433A (en) 2009-06-25
EA200200509A1 (en) 2002-10-31
IS2209B (en) 2007-02-15
EP1235825B1 (en) 2006-01-25
NZ518280A (en) 2004-05-28
EP1235825A1 (en) 2002-09-04
AT316528T (en) 2006-02-15
NO20022556D0 (en) 2002-05-29
ES2256052T3 (en) 2006-07-16
TWI258475B (en) 2006-07-21
DZ3327A1 (en) 2001-06-07
DE60025747D1 (en) 2006-04-13
SK7172002A3 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
KR880003016A (en) How to increase the energy supply in an electric arc
DE3650068D1 (en) Pharmaceutical carrier to reduce the transdermal flux.
DE60112553D1 (en) Biocompatible material compilation adaptable to different therapeutic uses
DE50114265D1 (en) Hard facing table
ES2124793T3 (en) Alkylated rapamycin derivatives oy use, particularly as immunosuppressants.
MX9704012A (en) Interferon conjugates.
DE60020865D1 (en) TELEPHONE WITH EMOTION DETECTOR FEEDBACK TO USER a
DE69026670D1 (en) Intelligent power supply system for a portable computer
EE200100284A (en) The reaction and crystallization to improve
NO961990D0 (en) An absorbent article with multidirectional stretchable side panels
AT260864T (en) Portable hydrogen source
RU2002118213A (en) adamantane derivatives
RU95118157A (en) Intelligent sensor powered by the current loop
AT313294T (en) Device for fast mapping the electrical activity in the heart
KR920021805A (en) How to remove the dye by oxygen in the secondary fiber recovery
AT268091T (en) Improvements to dmd-image display devices
KR910013669A (en) High efficiency bridge-type power converter
AT439044T (en) Small infant formula with increased alpha-lactalbumin-content
AT244995T (en) Table with pivotable tabletop
ES2177293T3 (en) Acid composition comprising beta-hydroxy-beta-methylbutyric and as a minimum an amino acid.
DK1282595T3 (en) To novel phenyl-propargylether derivatives
AR038427A2 (en) 15-alkyl-14-hydroxy compounds and paraherquamide marcfortine
DE60128508D1 (en) Transparent conductive film, transparent conductive sheet and touch panel
ID29696A (en) Disposable hygiene articles processes to provide these objects with parts connected by elastic leg openings
NO20014642L (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors